ArticleInternational journal of clinical and experimental medicine2015
Increased expressions of integrin subunit β1, β2 and β3 in patients with cancer ------correlation analysis between risk factors of VTE and expression of core proteins.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Bufalin inhibits glycolysis-induced cell growth and proliferation through the suppression of Integrin β2/FAK signaling pathway in ovarian cancer.American journal of cancer research · 2018Article
- Early diagnosis of venous thromboembolism as a clinical primary symptom of occult cancer: Core proteins of a venous thrombus.Oncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCancer is one of the most common risk factor of venous thromboembolism (VTE). Our previous studies have shown that integrin subunits β1, β2 and β3 were the core proteins of venous thrombi and potential useful biomarker of VTE. This study aimed to explore the expression status of core proteins (integrin subunits β1, β2 and β3) in cancer patients.
methodsThis is a case-control study. A total of 144 inpatients (54 females) with clinically proven cancers were recruited into this study, meanwhile 200 inpatients without cancer matched in sex and age were recruited as control group. Flow cytometry was done to measure the expressions of blood integrin β1, β2, β3 and cellular immunity related variables (CD3, CD4, CD8, CD4/CD8, CD16CD56 and CD19). The association degree between increased core proteins and cancers was analyzed by calculating the relative risk (RR).
resultsThe expression of integrin β1 and β3 were markedly increased in patients with cancer (P=0.001 and 0.008). Integrin β2 was also mildly increased in patients with cancer (P=0.274). The relative risk ratio (RR) of increased integrin β1, β2 and β3 in cancer patients was 1.655 (95% CI: 1.321-2.074, P=0.000), 1.314 (95% CI: 1.052-1.642, P=0.021) and 1.852, (95% CI: 1.097-3.126, P=0.028), respectively. Combined analysis with integrin β1, β2 and β3 showed that the relative risk ratio (RR) of increased in cancer patients was 4.895 (95% CI: 1.645-14.563, P=0.002). CD3, CD4, CD4/CD8 and CD19 were significantly decreased (P=0.004, P=0.000, P=0.000, P=0.000, respectively) in patients with cancer, while CD8 and CD16CD56 were markedly increased in cancer patients (P=0.005, P=0.035).
conclusionsAs the core proteins of venous thrombi, integrin β1 and β3 were markedly increased expression in patients with cancer, which maybe explain the increased risk of VTE in cancer patients. A weakened or disordered immune system might be the basis of VTE in condition.
Indexed as
Identifiers
25932233PMC4402880W416743688What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.